A study which shows that significantly more (63%) patients had children when EmbryoGlue® was used, compared with the control group, was presented at the ongoing ESHRE conference in Stockholm. Vitrolife's patented medium EmbryoGlue® is used when reintroducing embryos in connection with assisted fertilization.

We have now shown that EmbryoGlue® results in more babies being born compared with traditional products, irrespective of the day when the embryos are reintroduced, says Dr. Basak Balaban, who works at the American Hospital in Istanbul, Turkey.

The independent Cochrane report has previously shown that EmbryoGlue® has a positive effect on pregnancy frequency.

The study results were presented at the annual ESHRE conference (European Society of Human Reproduction and Embryology) that is being held in Stockholm this year. The conference started on Sunday and has brought together approximately 8,000 delegates from all over the world.

EmbryoGlue® is a patented product with a unique composition that includes hyaluronic acid and it is similar to the natural environment in the womb. The components that it contains provide the embryo with the necessary nutrients and sources of energy and make it easier for the reintroduced embryos to attach to the endometrium and develop into a foetus.

Vitrolife AB